Abstract | BACKGROUND: METHODS: Periodontal status was evaluated in 40 subjects with RA who were divided into two groups: Group I contained 20 subjects who had received infliximab every 6 weeks for > or =22 months at the time of periodontal evaluation. The 20 subjects in group II were evaluated before their first infusion with infliximab. Nine subjects in group II had periodontitis. These subjects were reevaluated after they received nine infusions of infliximab. RESULTS: CONCLUSIONS:
|
Authors | Jacques-Olivier Pers, Alain Saraux, Roselyne Pierre, Pierre Youinou |
Journal | Journal of periodontology
(J Periodontol)
Vol. 79
Issue 9
Pg. 1645-51
(Sep 2008)
ISSN: 0022-3492 [Print] United States |
PMID | 18771364
(Publication Type: Journal Article)
|
Chemical References |
- Antibodies, Monoclonal
- Antirheumatic Agents
- Tumor Necrosis Factor-alpha
- Infliximab
- Methotrexate
|
Topics |
- Adult
- Aged
- Antibodies, Monoclonal
(adverse effects, therapeutic use)
- Antirheumatic Agents
(adverse effects, therapeutic use)
- Arthritis, Rheumatoid
(drug therapy)
- Cross-Sectional Studies
- Dental Plaque Index
- Female
- Gingival Hemorrhage
(physiopathology)
- Gingivitis
(physiopathology)
- Humans
- Infliximab
- Longitudinal Studies
- Male
- Methotrexate
(therapeutic use)
- Middle Aged
- Periodontal Attachment Loss
(physiopathology)
- Periodontal Index
- Periodontal Pocket
(drug therapy, physiopathology)
- Periodontitis
(drug therapy, microbiology, physiopathology)
- Smoking
- Tumor Necrosis Factor-alpha
(antagonists & inhibitors)
|